AS
MRNA icon

AM Squared’s Moderna MRNA Stock Holding History

AM Squared’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$13.4K Buy
+200
New +$18.4K 0.03% 68

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

AM Squared's MRNA Position: Q3 2024 in Review

AM Squared opened a new position in Moderna (MRNA) in Q3 2024: 200 shares worth $13.4K. The stake represents 0.03% of the portfolio and ranks #68 among its holdings.

789 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • AM Squared held 200 shares of Moderna worth $13.4K as of Q3 2024.
  • Moderna was a new AM Squared position in Q3 2024.
  • Moderna made up 0.03% of AM Squared's portfolio in Q3 2024, its #68 holding.
  • 789 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on AM Squared's 13F filing for Q3 2024, filed 7 Nov 2024.